BLUEWILLOW BIOLOGICS INC — Department of Health and Human Services SBIR Phase II: 72
BLUEWILLOW BIOLOGICS INC — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $2,995,800
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- 72
- NAICS
- —
- Place of performance
- MI
- Period
- —
Description
Food allergy is an emerging health problem with increasing incidence and severity, particularly in children, and continuing throughout adulthood. Since 1990, the incidence of self-reported peanut allergy has risen significantly representing a mounting financial burden to the healthcare system. With no approved therapeutics available, various forms of immunotherapy have been evaluated but generally do not facilitate long-term protection and can have adverse side effects. BlueWillow will apply its oil-in-water NanoVax nanoemulsion mucosal adjuvant (NE01) to formulate a vaccine against peanut allergy. In this SBIR project, Phase I will consist of formulation activities and the evaluation of efficacy in a mouse model of peanut allergy. In phase II, the project will assess the long-term protection in preclinical animal models and engage in IND-enabling activities.